Skip to main content

Table 1 Characteristics of Studies Investigating Stroke Related to ADT

From: Stroke related to androgen deprivation therapy for prostate cancer: a meta-analysis and systematic review

First author year

Design, LOE

Database source (Duration)

Definition of Stroke (ICD codes)

Types of ADT

Treatments of control

No. of ADT/Control

Age ya(SD) of patients

Follow-up, (ya)

Hazard Ratios(95%CI)

Jespersen et al. [25] 2013

Cohort, 2a

Danish Cancer Registry (2002–2010)

Ischemic Stroke/TIA (ICD-8 codes 433, 434.09/99, 436.01/436.90, ICD-10 codes DI63.x, DI64.x)

GnRH/AA

non-ADT

9204

20,307

71

3.3 (1.8 to 5.2)

1.19(1.06,1.35)c

1.17 (0.94, 1.50)d

Orchiectomy

2060

1.11(0.90,1.36)c

Hemelrijck et al. [24] 2010

Cohort, 2a

NPCR of Sweden (1997–2007)

Stroke (ICD-10: 160–164, G45)

GnRH agonist

RP

9066

26,432

≤65: 19,153

3.8

4.4

1.21(1.11,1.32)b

1.16 (1.01, 1.32)d

AA

3391

4

0.88(0.76,1.00)b

GnRH + AA

WW/AS

11,646

19,527

66 to 74: 27,737

3.3

4.7

1.25(1.15,1.35)b

Orchiectomy

5340

≥75: 13,110

3.1

1.30(1.18,1.44)b

Other types

1199

-

-

Alibhai et al. [14] 2009

Cohort, 2a

ICES (1995–2005)

Stroke (ICD-9-CM codes 430–438)

ADT

non-ADT

19,079/19,079

75 ± 6.3

6.47

0.88(0.81,0.96)c

Keating et al. [23] 2010

Cohort, 2a

Veterans Healthcare Administration (2001–2004)

Ischemic Stroke/TIA (ICD-9 codes 433.XX −435.XX)

GnRH agonist

WW/AS

14,037

22,846

66.9 ± 8.6

2.6

1.18(1.02,1.36)c

1.18 (0.91, 1.51)d

AA

1229

0.89(0.46,1.73)c

GnRH + AA

1838

0.91(0.60,1.39)c

Orchiectomy

308

1.81(1.15,2.84)c

Huang et al. [21], 2014

Cohort, 2a

Queen Mary Hospital, Hong Kong (1998–2011)

Ischemic Stroke (NA)

ADT

non-ADT

517/228

72.2 ± 0.3

5.3

0.94 (0.35, 2.45)c

Azoulay et al. [13] 2011

Nested Case–control, 2a

GPRD (1988–2008)

Stroke/TIA (NA)

GnRH agonist

non-ADT

3274

3960

72.3 ± 3.9

3.9

1.18(1.00,1.39)c

1.34 (1.15, 1.55)d

AA

457

1.47(1.08,2.01)c

GnRH + AA

481

1.26(0.93,1.72)c

Orchiectomy

295

1.77(1.25,2.51)c

Other types

142

1.42(0.84,2.39)c

  1. Abbreviations: LOE level of evidence, ADT androgen deprivation therapy, GnRH gonadotropin-releasing hormone (leuteinizing hormone releasing hormone, LHRH), AA oral antiandrogens, RP radical prostatectomy/curative treatment, WW/AS watchful waiting (WW)/active surveillance (AS), SD standard deviation, NA not applicable, NPCR National Prostate Cancer Register, GPRD UK general practice research database, ICES institute for clinical evaluative sciences
  2. amean or median
  3. bcompared with WW/AS
  4. cHR was directly given in the publication
  5. dCombined estimates from all types of ADT with random effect meta-analysis